EffRx Pharmaceuticals

What EffRx Pharmaceuticals does

EffRx Pharmaceuticals SA is a commercial-stage Swiss specialty pharmaceutical company headquartered in Freienbach, Switzerland, focused on the late-stage development and commercialization of prescription medications for niche and orphan indications in endocrinology, rare diseases, and musculoskeletal disorders. The company's product portfolio centers on Binosto, a proprietary buffered effervescent alendronate tablet (the first and only buffered solution for osteoporosis treatment), alongside in-licensed rare disease therapies including Alkindi (pediatric hydrocortisone for adrenal insufficiency), Efmody (modified-release hydrocortisone for congenital adrenal hyperplasia), Miglustat Dipharma (for Gaucher disease and Niemann-Pick type C), and additional Swiss-marketed products (Dibase, Testavan, Lysodren, Metopiron). Binosto is distributed globally through exclusive licensing arrangements with regional partners (Radius Health in the US, Lupin in Vietnam/Philippines, Pyridam Farma in Indonesia, Compai Pharma in Malaysia), and has secured approximately 30 marketing authorizations worldwide.

The company operates a hybrid commercial model: direct sales infrastructure in Switzerland for its full niche portfolio, and out-licensing to specialized partners across international markets, with EffRx retaining product supply responsibilities. EffRx co-founded the World Orphan Drug Alliance (WODA) in May 2022, a distribution alliance covering 68 countries and 64 million potential rare disease patients across Central/Eastern Europe, the Middle East, North Africa, Russia/CIS, and Latin America. In May 2023, EffRx was acquired by Italian specialty pharma company Abiogen Pharma S.p.A., which is the controlling parent and provides strategic depth in osteoarticular and bone metabolism diseases. As of January 2025, EffRx has been awarded the EcoVadis Silver Medal, placing it in the top 15% of companies evaluated for sustainability management.

Name

EffRx Pharmaceuticals

Legal name

EffRx Pharmaceuticals SA

Website

https://effrx.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

EffRx Pharmaceuticals is a Swiss specialty pharmaceutical company commercializing niche and orphan medicines for endocrinology, rare diseases, and musculoskeletal disorders, combining direct Swiss sales with global out-licensing of its lead product, Binosto.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Specialty pharmaceuticals
• Rare disease therapeutics
• Osteoporosis treatments
• Orphan drug licensing
• Pediatric endocrinology medicines

Headquarters

HQ city

Freienbach

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Product Licensing and Royalty Revenue: EffRx generates revenue through exclusive licensing agreements with regional commercialization partners. The company grants licenses to commercialize Binosto in specific territories while maintaining product supply. Partners pay licensing fees and royalties for the right to commercialize the product.
2. Direct Product Sales in Switzerland: EffRx directly commercializes its portfolio of rare disease, endocrinology, and musculoskeletal treatments in Switzerland, including Alkindi, Miglustat Dipharma, Binosto, Dibase, Testavan, Lysodren, and Metopiron.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels4 records

Core offering

EffRx Pharmaceuticals commercializes a portfolio of niche and orphan prescription medicines focused on rare endocrine, metabolic, and musculoskeletal disorders. Its lead proprietary product is Binosto, a buffered soluble effervescent alendronate tablet for osteoporosis, complemented by in-licensed rare disease products (Alkindi for pediatric adrenal insufficiency, Efmody for congenital adrenal hyperplasia, Miglustat Dipharma for Gaucher disease and Niemann-Pick type C) and additional Swiss-marketed products (Dibase, Testavan, Lysodren, Metopiron). The company directly sells its portfolio in Switzerland and out-licenses Binosto to regional commercialization partners across multiple continents.

Product overview

EffRx Pharmaceuticals is a commercial-stage pharmaceutical company that markets a portfolio of prescription medications for rare endocrine, metabolic and musculoskeletal disorders. The company's product portfolio includes proprietary products (Binosto®) and in-licensed rare disease therapies (Alkindi®, Efmody®, Miglustat Dipharma®), along with additional musculoskeletal and rare disease products (Dibase®, Testavan®, Lysodren®, Metopiron®) marketed directly in Switzerland. EffRx focuses on late-stage development and commercialization, with Binosto® as the lead commercialized product for osteoporosis, distributed globally through licensing partnerships across Europe, US, Asia and Middle East.

Differentiator

Problem solved

Functional benefit

Products and services

• Binosto® Binosto® (buffered soluble alendronate 70 mg) is an effervescent tablet for oral solution indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. It is the first and only buffered solution for osteoporosis treatment, formulated to dissolve in water yielding a buffered oral solution (pH 4.8–5.4) that facilitates delivery to the stomach and reduces the potential for local and esophageal irritation compared with conventional alendronate tablets. Distributed globally through regional licensing partners.
• Alkindi® Alkindi® is an immediate-release hydrocortisone preparation specifically designed for pediatric patients with adrenal insufficiency. Available in color-coded capsules with four different dose strengths (0.5 mg, 1 mg, 2 mg, 5 mg), it enables individualized, accurate, and flexible dosing without the need for magisterial formulations or tablet fragmentation.
• Efmody® Efmody® is a modified-release preparation of hydrocortisone specifically designed for the treatment of patients with congenital adrenal hyperplasia (CAH). It mimics the body's natural cortisol circadian rhythm when given in a twice-a-day 'toothbrush' regimen.
• Miglustat Dipharma® Miglustat Dipharma® is an inhibitor of glucosylceramide synthase indicated for oral treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable, and for treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.
• Dibase® Dibase® is a vitamin D supplement marketed in Switzerland, available in 10,000 IU and 25,000 IU formulations for the treatment of vitamin D deficiency.
• Testavan® Testavan® is a testosterone replacement therapy product marketed in Switzerland for the treatment of testosterone deficiency.
• Lysodren® Lysodren® is a product for the treatment of adrenocortical carcinoma (ACC), marketed in Switzerland by EffRx.
• Metopiron® Metopiron® is a product for the treatment of Cushing Syndrome, marketed in Switzerland by EffRx.

Quantifiable outcome

• Binosto demonstrated greater persistence compared to alendronate tablets in postmenopausal women with osteoporosis
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core.

• Compai PharmacoreChannel Partner/ Reseller/ Distributor · 8 January 2026Exclusive licensing and distribution agreement for Binosto in Malaysia. Compai Pharma is a leading medical distribution company with strong reach across South East Asia. The partnership addresses underdiagnosis and undertreatment of osteoporosis in Malaysia.
• Pyridam Farma (PT Pyridam Farma Tbk)coreChannel Partner/ Reseller/ Distributor · 7 May 2024Exclusive license and distribution agreement for Binosto in Indonesia. Pyridam Farma is a leading public listed pharmaceutical company in Indonesia. The partnership aims to enhance healthcare access for osteoporosis patients and deliver innovative solutions to the Indonesian healthcare system.
• Lupin LimitedcoreChannel Partner/ Reseller/ Distributor · 6 February 2024Exclusive licensing and distribution agreement for Binosto in Vietnam and Philippines. Lupin, a leading global pharmaceutical company, will commercialize Binosto for postmenopausal osteoporosis treatment. EffRx will supply product to Lupin.
• Radius HealthcoreChannel Partner/ Reseller/ Distributor · 19 September 2023Exclusive licensing and distribution agreement for Binosto in the United States. Radius Health, a major player in the U.S. bone market with TYMLOS, gained rights to commercialize Binosto for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. EffRx will supply product to Radius.
• World Orphan Drug Alliance (WODA)coreStrategic or Co-development Partner · 12 May 2022WODA is a global alliance of regional full-service distributors for orphan drugs founded by EffRx together with Medis, Orpharm, Vector Pharma, and OrphanDC. The alliance covers 68 countries across Central/Eastern Europe, Latin America, Middle East/North Africa/Turkey, Russia/CIS, and Switzerland. WODA provides access to 64 million potential rare disease patients and offers full-service solutions including deep understanding of local healthcare systems and flexible partnership approaches.
• Diurnal Group plccoreOEM/ Whitelabel/ Licensing Partner · 26 April 2022Exclusive license agreement for registration and commercialization of Efmody (modified-release hydrocortisone) for congenital adrenal hyperplasia (CAH) in Switzerland. EffRx received exclusive rights to register and commercialize Efmody in Switzerland, with plans to submit MAA to Swissmedic for adolescent and adult patients (12 years and older).
• Dipharma SAcoreOEM/ Whitelabel/ Licensing Partner · 18 November 2020Exclusive license agreement for commercialization of Miglustat Dipharma in Switzerland. Miglustat Dipharma is a generic equivalent to Actelion's Zavesca for treatment of mild to moderate type 1 Gaucher disease and progressive neurological manifestations in Niemann-Pick type C disease. Product reimbursed in Switzerland as of November 2020.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Radius Health: US specialty pharma commercializing TYMLOS for postmenopausal osteoporosis. Radius is EffRx's exclusive US licensing and distribution partner for Binosto, putting the two companies in allied/complementary positions in the same osteoporosis market while Radius also serves as EffRx's go-to channel for US growth.
• Cumberland Pharmaceuticals: US-based specialty pharma commercializing niche prescription products for underserved indications (including metabolic and endocrine). Comparable business model of focused, small-team commercialization of specialty molecules through selective physician targets.
• Diurnal Group plc: UK-based specialty pharma focused on cortisol-related endocrine disorders (CAH, adrenal insufficiency). Diurnal both partners with EffRx (licenses Efmody to EffRx for Switzerland) and competes with EffRx's Alkindi in overlapping pediatric/adult hydrocortisone markets, making it the closest direct peer.
• Amryt Pharma (Chiesi): Specialty rare-disease pharma with EU/US commercial platform focused on metabolic, endocrine, and rare dermatology indications. Was acquired by Chiesi in 2023; serves a comparable target prescriber base of rare disease specialists as EffRx.
• HRA Pharma: Mid-sized European specialty pharma focused on rare endocrine disorders (especially adrenal insufficiency, Cushing's, CAH) and underserved therapeutic niches. Head-to-head competitor for similar prescribers in Switzerland and continental Europe.
• Orphan Europe (Recordati Group): European-focused orphan drug distributor commercializing treatments for rare endocrine, metabolic, and lysosomal storage disorders via in-licensing. Closely mirrors EffRx's model of bringing orphan drugs to European patients with unmet needs.

Broad incumbents

• Recordati Rare Diseases: Specialty division of Recordati Group focused on rare diseases with broad European commercial platform and marketed endocrine/metabolic products. Comparable business model of in-licensing rare disease products and distributing across Europe through field sales.
• Sobi (Swedish Orphan Biovitrum): Large European rare-disease specialty pharma with established commercial footprint in endocrine and metabolic rare diseases (e.g., Kineret, Somavert). Operates broadly in the same orphan-drug commercialization model that EffRx uses in Switzerland, but at far larger scale and product breadth.
• Kyowa Kirin International: Specialty pharma with established European presence in rare endocrine and metabolic disorders (e.g., Crysvita, Poteligeo). Uses a niche in-licensing and orphan commercialization playbook comparable to EffRx's, but at much greater scale.

Emerging players

• Dipharma SA: Italian pharmaceutical company specializing in generic and rare disease products (Miglustat Dipharma originator). Licenses Miglustat Dipharma to EffRx for Switzerland and operates the same rare-disease/orphan commercial philosophy; partial overlap creates both partnership and competitor dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/effrx-pharmaceuticals-sa
• Xx.com/EffRx

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EffRx Pharmaceuticals